Invesco Biotechnology & Genome ETF

Incyte Celebrates 2025 MPN Heroes at ASH Annual Meeting

Stoke Therapeutics and Biogen Show Positive Data for Dravet Syndrome Drug

Tema Etfs LLC Increased Holdings in Amgen Inc.

First Trust Advisors LP Reduced Holdings in Amgen Inc. in Q2

Biogen CEO Purchases Company Stock

VestGen Advisors Significantly Reduces Holdings in Gilead Sciences, CEO Sells Shares

Denali Therapeutics and Royalty Pharma Reach $275 Million Financing Agreement

Ionis Pharmaceuticals Director Sold Company Common Stock

Royalty Pharma CFO sells company stocks

Biogen advances immunology pipeline, felzartamab shows promise in multiple diseases

Amgen Reports Strong Revenue and Sales Growth, BMO Raises Target Price

Sanofi and Regeneron Obtain EU Approval for Dupixent to Treat Chronic Urticaria

Goldman Sachs Reiterates Buy Rating and Price Target for Amgen

Biogen and Eisai Showcase LEQEMBI's Pharmacological Effect on Alzheimer's Patients

Sorrento Therapeutics Outlines Jakafi Follow-Up Growth Strategy

Sette Healthcare Collaborates with Winnie Harlow for Vitiligo Awareness Campaign

OMERS ADMINISTRATION Corp reduces stake in Amgen

Prossimo Advisors LLC Invests in Gilead Sciences

Gilead Sciences CEO Sells Company Shares

Round Hill Asset Management Reduces Stake in Amgen

SMX Security Matters

Wheeler Real Estate

Gulf Resources

Treasure Gbl

Dreamland

Irobot

Praxis Precision Medicines

DigitalBridge

Click Holdings/BVI

ChargePoint

INCY

Incyte Corporation celebrated the 2025 MPN Heroes at the 67th ASH Annual Meeting in Orlando, recognizing eight individuals and organizations for their significant contributions to the myeloproliferative neoplasm (MPN) community. The event highlighted Incyte's commitment to MPN advocacy and care, featuring a poster session from leading advocacy groups. This recognition program underscores Incyte's dedication to advancing community and treatment solutions for those affected by MPNs.

Reuters

Incyte

Incyte Honors 2025 MPN Heroes at ASH Annual Meeting

STOK

BIIB

Stoke Therapeutics and Biogen presented positive data on zorevunersen for Dravet syndrome at the AES 2025 Meeting. The data showed increased seizure-free days and improved quality of life for patients. Further safety and efficacy data are expected from the ongoing Phase 3 EMPEROR program.

Stoke Therapeutics

Biogen

Stoke Therapeutics and Biogen Present Positive Zorevunersen Data for Dravet Syndrome at AES 2025 Meeting

AMGN

Tema Etfs LLC increased its holdings in Amgen Inc. by 33.3% in Q2, owning 12,977 shares worth $3.62 million. Analysts have mixed ratings on Amgen, with a consensus target price of $335.65. Amgen reported strong quarterly earnings, beating estimates with $5.64 EPS and $9.56 billion revenue. The company announced a quarterly dividend of $2.38 per share, yielding 2.8%. Amgen's stock performance shows a one-year high of $346.38.

Market Beat

Amgen

Tema Etfs LLC Has $3.62 Million Stock Holdings in Amgen Inc. $AMGN

First Trust Advisors LP reduced its stake in Amgen Inc. by 3.8% in Q2, selling 21,347 shares. Amgen's stock opened at $340.16, with a market cap of $183.17 billion. The company reported Q3 earnings of $5.64 per share, beating estimates, and announced a quarterly dividend of $2.38. Insiders sold shares, including EVP Murdo Gordon and SVP Rachna Khosla.

First Trust Advisors LP Sells 21,347 Shares of Amgen Inc. $AMGN

BCRX

BioCryst Pharmaceuticals insider Alane Barnes sold 50,906 shares at $7.21 each, totaling $367,032.26, reducing her stake by 12.23%. Post-sale, she holds 365,246 shares valued at $2,633,423.66. The sale was disclosed in an SEC filing. BioCryst's stock rose 9.6% to $7.85, with a trading volume of 7.6 million shares. Analysts have mixed ratings, with a consensus target price of $19.33. Institutional investors have adjusted their stakes in the company.

BioCryst Pharma

Insider Selling: BioCryst Pharmaceuticals (NASDAQ:BCRX) Insider Sells 50,906 Shares of Stock

Incyte Corp. (INCY) shares fell 1.02% to $100.46 on Thursday, despite a mixed trading session where the S&P 500 rose 0.11% and the Dow Jones fell 0.07%. The stock is 8.07% below its 52-week high. Competitors like Alnylam Pharmaceuticals, Bio-Techne, and BioMarin Pharmaceutical also saw declines. Trading volume was below the 50-day average.

Dow Jones

Incyte Corp. Stock Outperforms Competitors Despite Losses On The Day

GILD

Gilead Sciences Inc. (GILD) shares fell 1.90% to $122.62 on Thursday, underperforming compared to competitors. The S&P 500 Index rose 0.11%, while the Dow Jones Industrial Average fell 0.07%. Gilead's stock is 4.72% below its 52-week high. Trading volume was 4.9M, below the 50-day average of 7.3M. Competitors' performances: Johnson & Johnson (JNJ) fell 1.39%, Pfizer Inc. (PFE) rose 0.51%, and Abbott Laboratories (ABT) rose 0.09%. Data source: Dow Jones Market Data, FactSet. Compiled December 4, 2025.

Gilead Sciences

Gilead Sciences Inc. Stock Underperforms Thursday When Compared To Competitors

ABBV

Amgen Inc. shares fell 1.52% to $340.16 on Thursday, underperforming compared to competitors. The S&P 500 Index rose 0.11%, while the Dow Jones Industrial Average fell 0.07%. Amgen's stock ended a two-day winning streak and closed 1.80% below its 52-week high. Competitors' performances varied: Johnson & Johnson fell 1.39%, Pfizer rose 0.51%, and AbbVie fell 0.66%. Trading volume was 3.4 million, above the 50-day average of 2.5 million.

Johnson & Johnson

Abbvie

Amgen Inc. Stock Underperforms Thursday When Compared To Competitors

UTHR

Martine A. Rothblatt, Chairman of United Therapeutics Corp, filed a Form 144 with the SEC to sell 4,000 shares on December 4, 2025, through TD Securities (USA) Inc. The sale is executed under a prearranged trading plan (10b5-1).

United Therap

Chmn Rothblatt Files To Sell 4,000 Of United Therapeutics Corp [UTHR]

Biogen's Alzheimer's treatments, targeting amyloid deposits, have shown a 30% delay in disease progression, unlike Novo Nordisk's semaglutide, which offered no cognitive benefits for early patients.1On December 3, 2025, Biogen CEO Christopher Viehbacher acquired 3,636 shares, increasing his total to 16,443. Some shares were surrendered to cover option costs and taxes.2

TradingView

Key facts: Biogen's Alzheimer's drug delays progression by 30%; CEO boosts shares

ALNY

Alnylam Pharmaceuticals (ALNY) stock has surged 12% in the past month and nearly doubled over the past year, raising questions about its valuation. The stock is priced at $473, slightly below Wall Street's target of $489, suggesting a modest 3.2% undervaluation. However, a DCF model indicates a 21% undervaluation with a fair value near $601. The growth is driven by AMVUTTRA's uptake and RNAi therapies' market expansion. Risks include pricing pressure and high R&D costs. Investors are advised to consider other innovative healthcare stocks.

Simplywall

Alnylam Pharma

Alnylam Pharmaceuticals (ALNY): Is the Stock’s Recent Surge Justified by Its Valuation?

VestGen Advisors LLC reduced its stake in Gilead Sciences by 93.2% in Q2, now holding 1,866 shares worth $207,000. Other investors adjusted their positions, with some increasing holdings significantly. Analysts have given Gilead a "Moderate Buy" rating with a consensus price target of $130.65. Insider trading included CEO Daniel O'Day selling 10,000 shares. Gilead's stock opened at $125.00, with a market cap of $155.09 billion.

VestGen Advisors LLC Lowers Holdings in Gilead Sciences, Inc. $GILD

BioCryst Pharmaceuticals Inc. has granted stock options and RSUs to four new employees. The options cover 57,100 shares with an exercise price of $7.13, and RSUs cover 46,400 shares. Both will vest in four annual installments starting from the first anniversary of the grant date, December 1, 2025. Each option has a 10-year term.

BioCryst Grants New Hires Stock Options and RSUs as Inducement

Biogen and Eisai presented new LEQEMBI data at the CTAD conference, highlighting long-term benefits in Alzheimer's progression and a new subcutaneous formulation. This could enhance Biogen's investment narrative by potentially improving treatment uptake. However, challenges remain with Alzheimer's uptake, reimbursement, and competition. Biogen's collaboration with Dayra Therapeutics aims to diversify its pipeline. Despite LEQEMBI's promising data, investors should consider pricing and reimbursement pressures on specialty drugs. Biogen's projected revenue is $9.4 billion by 2028, with varied community valuations reflecting differing expectations.

Should New LEQEMBI Data and Subcutaneous Option Shift the Risk Profile for Biogen (BIIB) Investors?